Compassionate Access and Expanded Access — Getting an Unapproved Cancer Drug in India

No, they are different pathways. A clinical trial is a structured research study testing whether a drug is safe and effective, and you must meet specific eligibility criteria set by the trial protocol. Compassionate access is for patients who cannot enter a trial and have already tried other licensed options. In a trial the drug is free and you receive close monitoring throughout; in compassionate access the supply terms and cost depend entirely on the manufacturer. Your oncologist can tell you whether a relevant trial is currently open before you pursue the compassionate access route.

Most programs require an application from a licensed oncologist or hospital, not from the patient or family directly. This is because the company needs verified clinical documentation and needs to communicate with the treating team about supply and any monitoring requirements. You can research which programs exist for a particular drug and ask your oncologist to apply, but the application must come through the hospital. A counsellor who has submitted these applications before will know exactly what each company requires and how to present the case.

There is no fixed timeline. It depends on how quickly the manufacturer confirms they will supply the drug, and how complete the application is when submitted. Weeks is a realistic minimum; the process can take longer when the manufacturer needs time to assess the case or when additional documentation is requested. If speed is critical, a pharmaceutical company's own patient assistance program — which does not require a separate CDSCO approval step — may be the faster route for drugs that are already approved elsewhere. Ask your counsellor which route is likely to move faster for the specific drug you are asking about.

Both schemes update their drug and procedure lists periodically, but many newer cancer drugs are not yet included. If your drug is not listed, the options include a pharmaceutical company patient assistance program if one exists for that drug, the CDSCO compassionate use route if the drug has not been approved in India at all, or paying out of pocket while asking whether the hospital has any institutional discount arrangements. Some hospitals also maintain charitable funds for patients in financial hardship — ask your counsellor whether that exists at your treating centre.

No. CION does not stock, supply, or administer unapproved drugs. That is governed by CDSCO and the drug manufacturer. What CION counsellors do is handle the application and follow-up process — approaching companies, compiling documentation, and checking scheme eligibility — so that if a program or approval pathway exists, you are better placed to access it. Immunotherapy that is already approved and indicated for your cancer is given as day care at CION centres in the usual way.

A refusal from a pharmaceutical company is not subject to a formal appeal in the same way a government scheme decision would be, but a revised application with additional clinical documentation or a direct conversation between your oncologist and the company's medical affairs team can sometimes change the outcome. Your oncologist may also know of a different manufacturer with a similar drug. If CDSCO declines, ask whether there is an alternative route, such as a currently open expanded access protocol or a trial that has recently opened. A counsellor who handles these cases regularly is better placed than a family member to identify what options remain.